These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10522981)

  • 1. Hormonal signaling in prostatic hyperplasia and neoplasia.
    Marcelli M; Cunningham GR
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3463-8. PubMed ID: 10522981
    [No Abstract]   [Full Text] [Related]  

  • 2. [Importance of various factors in the occurrence of prostatic cancer].
    Chaklin AV; Plotnikov SV
    Urol Nefrol (Mosk); 1984; (4):46-51. PubMed ID: 6206634
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical approaches in the management of prostatic disease.
    Droller MJ
    Br J Urol; 1997 Apr; 79 Suppl 2():42-52. PubMed ID: 9126069
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogenesis of prostatic hyperplasia and neoplasia.
    Roberts HJ
    Geriatrics; 1967 Dec; 22(12):85-92. PubMed ID: 4168607
    [No Abstract]   [Full Text] [Related]  

  • 5. Hormonal implications in the development and treatment of prostate cancer.
    Ip C; Hall SJ
    Endocrinol Metab Clin North Am; 2007 Jun; 36(2):421-34. PubMed ID: 17543727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Androgens].
    Shida K; Ito Z; Yamanaka H
    Horumon To Rinsho; 1975 Dec; 23(12):1203-19. PubMed ID: 55321
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hormonal receptors and other procedures for predicting clinical response in cancer of the prostate].
    Habib FK; Chisholm GD
    Arch Esp Urol; 1984 Dec; 37 Suppl 2():751-9. PubMed ID: 6085672
    [No Abstract]   [Full Text] [Related]  

  • 8. An organ-culture technique for the investiation of hormonal dependence in human prostatic neoplasia.
    McMahon MJ; Thomas GH
    Br J Surg; 1970 Nov; 57(11):860. PubMed ID: 4098286
    [No Abstract]   [Full Text] [Related]  

  • 9. Endocrine and adrenergic pharmacological intervention in diseases of the prostate.
    Rane A
    Br J Clin Pharmacol; 1998 Apr; 45(4):329-37. PubMed ID: 9578179
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical endocrinology of prostatic tumors.
    Voigt KD; Krieg M
    Curr Top Exp Endocrinol; 1978; 3():173-99. PubMed ID: 77753
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancer, gonadal hormones, and my brain.
    Wassersug RJ
    J Sex Marital Ther; 2014; 40(5):355-7. PubMed ID: 24846435
    [No Abstract]   [Full Text] [Related]  

  • 12. [The role of tissue steroids in benign hyperplasia and prostate cancer].
    Voigt KD; Bartsch W
    Urologe A; 1987 Nov; 26(6):349-57. PubMed ID: 2448941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate diseases--role of sex steroids and their inhibitors.
    Welén K; Damber JE
    Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation as a strategy for prostate cancer chemoprevention.
    Aquilina JW; Lipsky JJ; Bostwick DG
    J Natl Cancer Inst; 1997 May; 89(10):689-96. PubMed ID: 9168183
    [No Abstract]   [Full Text] [Related]  

  • 15. Pressure effects on cellular systems: is there a link with benign prostatic hyperplasia?
    Hegarty P; Watson RW; Hegarty NJ; Coffey RN; Fitzpatrick JM
    Urology; 2004 Aug; 64(2):195-200. PubMed ID: 15302460
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgens and prostate cancer: biology, pathology and hormonal therapy.
    Galbraith SM; Duchesne GM
    Eur J Cancer; 1997 Apr; 33(4):545-54. PubMed ID: 9274433
    [No Abstract]   [Full Text] [Related]  

  • 17. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer.
    Zhang L; Zhou J; Fan S; Liang CZ
    Asian J Androl; 2016; 18(4):654-6. PubMed ID: 26208396
    [No Abstract]   [Full Text] [Related]  

  • 19. Endocrine therapy: where do we stand and where are we going?
    Schröder FH
    Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.